Despite recent therapeutic advances including SGLT2 inhibitors, vericiguat, and transcatheter mitral valve repair, HFrEF continues to have high morbidity and mortality.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on HFrEF treatmentMore from JAMA